Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019

Objective The aim of this study was to report the use casirivimab/imdevimab therapy in pregnant women with moderate coronavirus disease 2019 (COVID-19). Study Design We report 12 cases of unvaccinated pregnant patients with mild-to-moderate COVID-19 treated with casirivimab/imdevimab. Results Twelve unvaccinated pregnant patients with mild-to-moderate COVID- 19 received casirivimab/imdevimab at the dose of 1200/1200mg by intravenous infusion over 60minutes. All women were managed outpatient. None experienced severe adverse drug reaction and none progressed to severe disease. Conclusion Casirivimab/imdevimab should be considered for outpatient treatment of unvaccinated pregnant womenwithmild-to-moderate COVID-19 to decrease the risk of severe disease.